On the public citation graph

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

https://doi.org/10.1038/sj.bjc.6602258
0 signed · 635 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/(sici)1097-0142(19970201)79:3<462::aid-cncr6>3.0.co;2-kopenalex-snapshot
Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma
inferredcites →https://doi.org/10.1002/(sici)1097-0142(19970401)79:7<1329::aid-cncr9>3.0.co;2-bopenalex-snapshot
Altered retinoblastoma protein expression in nonsmall cell lung cancer
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19970422)74:2<162::aid-ijc4>3.0.co;2-xopenalex-snapshot
Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19970620)74:3<330::aid-ijc17>3.0.co;2-fopenalex-snapshot
Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19980619)79:3<269::aid-ijc10>3.0.co;2-3openalex-snapshot
Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma
inferredcites →https://doi.org/10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8openalex-snapshot
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
inferredcites →https://doi.org/10.1002/1097-0142(19920101)69:1<72::aid-cncr2820690114>3.0.co;2-aopenalex-snapshot
Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer
inferredcites →https://doi.org/10.1002/1097-0142(19930715)72:2<432::aid-cncr2820720219>3.0.co;2-#openalex-snapshot
K‐ ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung
inferredcites →https://doi.org/10.1002/1097-0142(19951215)76:12<2457::aid-cncr2820761209>3.0.co;2-xopenalex-snapshot
Prognostic significance of p53 andras p21 expression in nonsmall cell lung cancer
inferredcites →https://doi.org/10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6openalex-snapshot
Prognostic factors for patients with small cell lung carcinoma
inferredcites →https://doi.org/10.1002/cncr.10387openalex-snapshot
Trimodality treatment in Stage III nonsmall cell lung carcinoma
inferredcites →https://doi.org/10.1007/bf00190558openalex-snapshot
K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma
inferredcites →https://doi.org/10.1007/s004320050208openalex-snapshot
Analysis of K -ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome
inferredcites →https://doi.org/10.1016/0169-5002(94)90325-5openalex-snapshot
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients
inferredcites →https://doi.org/10.1016/0169-5002(95)00421-vopenalex-snapshot
Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in Stage IIIA non-small cell lung cancer
inferredcites →https://doi.org/10.1016/0169-5002(95)96453-3openalex-snapshot
c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung
inferredcites →https://doi.org/10.1016/s0033-0620(85)80003-7openalex-snapshot
Beta blockade during and after myocardial infarction: An overview of the randomized trials
inferredcites →https://doi.org/10.1016/s0169-5002(96)80041-9openalex-snapshot
Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
inferredcites →https://doi.org/10.1016/s0169-5002(98)00086-5openalex-snapshot
The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients
inferredcites →https://doi.org/10.1016/s0169-5002(99)00009-4openalex-snapshot
Study of prognostic predictors for non-small cell lung cancer
inferredcites →https://doi.org/10.1016/s0304-3835(02)00740-1openalex-snapshot
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients
inferredcites →https://doi.org/10.1016/s0889-8588(05)70441-xopenalex-snapshot
PROGNOSTIC MARKERS IN RESECTABLE NON–SMALL CELL LUNG CANCER
inferredcites →https://doi.org/10.1016/s0959-8049(03)00232-6openalex-snapshot
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers
inferredcites →https://doi.org/10.1038/bjc.1997.194openalex-snapshot
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/bjc.1997.31openalex-snapshot
Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/sj.bjc.6600551openalex-snapshot
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
inferredcites →https://doi.org/10.1038/sj.bjc.6601095openalex-snapshot
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis
inferredcites →https://doi.org/10.1038/sj.bjc.6601252openalex-snapshot
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature
inferredcites →https://doi.org/10.1038/sj.onc.1202556openalex-snapshot
A novel molecular staging protocol for non-small cell lung cancer
inferredcites →https://doi.org/10.1054/bjoc.2000.1287openalex-snapshot
Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer
inferredcites →https://doi.org/10.1056/nejm199008303230902openalex-snapshot
K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
inferredcites →https://doi.org/10.1067/mtc.2002.120343openalex-snapshot
Molecular assessment of lymph nodes in patients with resected stage I non–small cell lung cancer: Preliminary results of a prospective study
inferredcites →https://doi.org/10.1093/annonc/6.suppl_3.s15openalex-snapshot
K-ras genotypes and prognosis in non-small-cell lung cancer
inferredcites →https://doi.org/10.1093/carcin/20.8.1507openalex-snapshot
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases
inferredcites →https://doi.org/10.1093/jnci/91.23.2032openalex-snapshot
Implications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
inferredcites →https://doi.org/10.1097/00000421-199804000-00013openalex-snapshot
Prognostic Value of K-ras Mutations, ras Oncoprotein, and c-erb B-2 Oncoprotein Expression in Adenocarcinoma of the Lung
inferredcites →https://doi.org/10.1097/00019606-199702000-00010openalex-snapshot
Clinicopathologic Analysis of k-ras, p53, and ERBB-2 Gene Alterations in Pulmonary Adenocarcinoma
inferredcites →https://doi.org/10.1101/gad.947701openalex-snapshot
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
inferredcites →https://doi.org/10.1159/000227461openalex-snapshot
Studies on Clinicopathological Features of Lung Cancer Patients with K-ras/p53 Gene Alterations: Comparison between Younger and Older Groups
inferredcites →https://doi.org/10.1164/ajrccm.157.4.9707108openalex-snapshot
Do Molecular Markers Predict Survival in Non–Small-Cell Lung Cancer?
inferredcites →https://doi.org/10.1164/ajrccm/142.6_pt_2.s27openalex-snapshot
The ras Oncogenes in Human Lung Cancer
inferredcites →https://doi.org/10.1172/jci117001openalex-snapshot
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
inferredcites →https://doi.org/10.1183/09031936.01.00062201openalex-snapshot
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
inferredcites →https://doi.org/10.1183/09031936.02.00296502openalex-snapshot
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
inferredcites →https://doi.org/10.1183/09031936.95.08081389openalex-snapshot
Molecular and biological factors in the prognosis of non-small cell lung cancer
inferredcites →https://doi.org/10.1200/jco.1995.13.5.1221openalex-snapshot
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
inferredcites →https://doi.org/10.1200/jco.1997.15.1.285openalex-snapshot
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
inferredcites →https://doi.org/10.1200/jco.1998.16.7.2468openalex-snapshot
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
inferredcites →https://doi.org/10.1200/jco.1999.17.2.668openalex-snapshot
Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1200/jco.2001.19.2.448openalex-snapshot
Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
inferredcites →https://doi.org/10.1200/jco.2002.09.147openalex-snapshot
Clinical Significance of p21 Expression in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.3346/jkms.2001.16.4.417openalex-snapshot
The Relationship between Microvessel Count and the Expression of Vascular Endothelial Growth Factor, p53, and K-ras in Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.3892/ijo.12.3.553openalex-snapshot
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
inferredcites →https://doi.org/10.3892/ijo.16.3.501openalex-snapshot
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
inferredcites →https://doi.org/10.3892/ijo.2.5.767openalex-snapshot
PROGNOSTIC VALUE OF ONCOPROTEINS FOR THE SURVIVAL OF PATIENTS WITH NONSMALL CELL LUNG CARCINOMAS

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4634802openalex-extracted
Validation and Modification of an Established Nomogram of Resected Non-Small Cell Lung Cancer Based on Genotypes
inferred← citeshttps://doi.org/10.1001/jama.2017.3438openalex-snapshot
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS -Mutant Advanced Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1002/9780470015902.a0025010openalex-snapshot
Ras Mutations in Cancer
inferred← citeshttps://doi.org/10.1002/9780470696330.ch10openalex-snapshot
Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer
inferred← citeshttps://doi.org/10.1002/ajmg.a.34419openalex-snapshot
Characterization of a novel KRAS mutation identified in Noonan syndrome
inferred← citeshttps://doi.org/10.1002/cam4.191openalex-snapshot
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung
inferred← citeshttps://doi.org/10.1002/cam4.2175openalex-snapshot
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas
inferred← citeshttps://doi.org/10.1002/cam4.2897openalex-snapshot
Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
inferred← citeshttps://doi.org/10.1002/cncr.26010openalex-snapshot
Clinicopathological features of lung adenocarcinoma with KRAS mutations
inferred← citeshttps://doi.org/10.1002/cncr.26456openalex-snapshot
Predictive clinical outcome of the intratumoral CD66b‐positive neutrophil‐to‐CD8‐positive T‐cell ratio in patients with resectable nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.27409openalex-snapshot
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
inferred← citeshttps://doi.org/10.1002/cncr.27730openalex-snapshot
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
inferred← citeshttps://doi.org/10.1002/cncr.28039openalex-snapshot
The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1002/cncr.28288openalex-snapshot
Oncogenic mutations in cervical cancer
inferred← citeshttps://doi.org/10.1002/cncr.29856openalex-snapshot
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with K RAS‐activated tumors
inferred← citeshttps://doi.org/10.1002/dc.22858openalex-snapshot
Respiratory cytology in the era of molecular diagnostics: A review
inferred← citeshttps://doi.org/10.1002/ijc.23343openalex-snapshot
MicroRNAs and cancer: Profile, profile, profile
inferred← citeshttps://doi.org/10.1002/ijc.26164openalex-snapshot
Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer
inferred← citeshttps://doi.org/10.1002/ijc.29195openalex-snapshot
Germline polymorphisms and survival of lung adenocarcinoma patients: A genome‐wide study in two European patient series
inferred← citeshttps://doi.org/10.1002/mc.22521openalex-snapshot
Polymeric black tea polyphenols (PBPs) inhibit benzo(a)pyrene and 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐ butanone‐induced lung carcinogenesis potentially through down‐regulation of p38 and Akt phosphorylation in A/J mice
inferred← citeshttps://doi.org/10.1002/ssu.10039openalex-snapshot
Translational research in lung cancer
inferred← citeshttps://doi.org/10.1007/174_2011_296openalex-snapshot
Translational Research in Lung Cancer
inferred← citeshttps://doi.org/10.1007/174_2011_310openalex-snapshot
Molecular Biology and Genetics of Lung Cancer
inferred← citeshttps://doi.org/10.1007/174_2022_346openalex-snapshot
Translational Research in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-0-387-72114-9_2openalex-snapshot
Molecular Genetics of Lung and Pleural Neoplasms
inferred← citeshttps://doi.org/10.1007/978-0-387-72430-0_16openalex-snapshot
Molecular Oncogenesis of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-0-387-72430-0_18openalex-snapshot
Prognostic Markers
inferred← citeshttps://doi.org/10.1007/978-0-387-88441-7_25openalex-snapshot
Lung
inferred← citeshttps://doi.org/10.1007/978-0-387-88443-1_25openalex-snapshot
Lung
inferred← citeshttps://doi.org/10.1007/978-0-85729-697-9_8openalex-snapshot
Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4419-0787-5_14openalex-snapshot
Molecular Pathology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4419-9755-5_8openalex-snapshot
Markers in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-3197-8_11openalex-snapshot
Molecular Prognostic Markers of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4614-3197-8_13openalex-snapshot
Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/978-1-4614-8778-4_5openalex-snapshot
A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
inferred← citeshttps://doi.org/10.1007/978-1-4939-1607-8_8openalex-snapshot
New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material
inferred← citeshttps://doi.org/10.1007/978-1-59745-184-0_24openalex-snapshot
Angiogenesis Inhibitors for the Treatment of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-59745-356-1_7openalex-snapshot
The intersection of EGFR and the Ras signaling pathway
inferred← citeshttps://doi.org/10.1007/978-1-59745-458-2_28openalex-snapshot
Molecular Basis of Lung Carcinogenesis
inferred← citeshttps://doi.org/10.1007/978-1-60761-524-8_12openalex-snapshot
Other Molecular Targeted Agents in Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60761-524-8_15openalex-snapshot
Lung Cancer Resistance to Chemotherapy
inferred← citeshttps://doi.org/10.1007/978-1-61779-612-8_13openalex-snapshot
Clinical Implications of Epigenetic Alterations in Human Thoracic Malignancies: Epigenetic Alterations in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-2-287-99041-0_8openalex-snapshot
Facteurs prédictifs pour un traitement personnalisé des cancers bronchiques non à petites cellules
inferred← citeshttps://doi.org/10.1007/978-3-030-17832-1_10openalex-snapshot
KRAS-Mutated Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-31503-0_8openalex-snapshot
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
inferred← citeshttps://doi.org/10.1007/978-3-319-06062-0_11openalex-snapshot
Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-24223-1_8openalex-snapshot
KRAS-Mutant Lung Cancers in the Era of Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-24932-2_11openalex-snapshot
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
inferred← citeshttps://doi.org/10.1007/978-3-319-35153-7_19openalex-snapshot
Epidemiology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-46091-8_2openalex-snapshot
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-62941-4_18openalex-snapshot
Prognostic Biomarkers in Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-76478-8_8openalex-snapshot
Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-3-540-31209-3_8openalex-snapshot
The Ras Signalling Pathway as a Target in Cancer Therapy
inferred← citeshttps://doi.org/10.1007/978-94-007-5842-1_1openalex-snapshot
Genomic Pathology of Lung Cancer
inferred← citeshttps://doi.org/10.1007/978-981-96-2763-9_2openalex-snapshot
Involvement of Mitogen-Activated Protein (MAP) Kinase Pathway in the Etiopathogenesis of Cancer and Its Role in Cancer Therapeutics
inferred← citeshttps://doi.org/10.1007/s00204-010-0562-4openalex-snapshot
EP4 upregulation of Ras signaling and feedback regulation of Ras in human colon tissues and cancer cells
inferred← citeshttps://doi.org/10.1007/s00280-024-04728-7openalex-snapshot
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor
inferred← citeshttps://doi.org/10.1007/s00432-013-1425-1openalex-snapshot
High circulating VEGF level predicts poor overall survival in lung cancer
inferred← citeshttps://doi.org/10.1007/s00432-015-1910-9openalex-snapshot
Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis
inferred← citeshttps://doi.org/10.1007/s00432-022-04455-7openalex-snapshot
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
inferred← citeshttps://doi.org/10.1007/s00595-013-0589-2openalex-snapshot
The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance
inferred← citeshttps://doi.org/10.1007/s00595-015-1295-zopenalex-snapshot
Mutations of the EGFR, K-ras, EML4–ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s10405-005-0027-2openalex-snapshot
Prognosefaktoren beim Lungenkarzinom
inferred← citeshttps://doi.org/10.1007/s10555-010-9209-4openalex-snapshot
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
inferred← citeshttps://doi.org/10.1007/s10555-020-09903-9openalex-snapshot
Current therapy of KRAS-mutant lung cancer
inferred← citeshttps://doi.org/10.1007/s10637-014-0163-9openalex-snapshot
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s11033-011-1332-yopenalex-snapshot
Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature
inferred← citeshttps://doi.org/10.1007/s11033-022-07766-7openalex-snapshot
Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update
inferred← citeshttps://doi.org/10.1007/s11654-011-0335-4openalex-snapshot
Molekularpathologische Grundlagen für die Therapie des NSCLC
inferred← citeshttps://doi.org/10.1007/s11912-010-0118-zopenalex-snapshot
Molecular Testing in Lung Cancer: The Time Is Now
inferred← citeshttps://doi.org/10.1007/s11912-013-0326-4openalex-snapshot
New Targets in Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s12032-015-0489-yopenalex-snapshot
The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s12032-016-0771-7openalex-snapshot
Rap2B promotes cell proliferation, migration and invasion in prostate cancer
inferred← citeshttps://doi.org/10.1007/s12094-013-1143-9openalex-snapshot
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
inferred← citeshttps://doi.org/10.1007/s12094-014-1235-1openalex-snapshot
A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12094-019-02175-yopenalex-snapshot
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s12254-012-0050-zopenalex-snapshot
Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012
inferred← citeshttps://doi.org/10.1007/s12254-014-0132-1openalex-snapshot
Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)
inferred← citeshttps://doi.org/10.1007/s12325-010-0103-9openalex-snapshot
Mind-mapping for lung cancer: Towards a personalized therapeutics approach
inferred← citeshttps://doi.org/10.1007/s13193-011-0108-0openalex-snapshot
Targetable “Driver” Mutations in Non Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s13273-014-0008-9openalex-snapshot
Expression profiling and pathway analysis of microRNA expression in the lungs of mice exposed to long-term, low-dose benzo(a)pyrene
inferred← citeshttps://doi.org/10.1007/s13277-012-0465-5openalex-snapshot
EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
inferred← citeshttps://doi.org/10.1007/s13277-013-0721-3openalex-snapshot
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival
inferred← citeshttps://doi.org/10.1007/s13277-014-2301-6openalex-snapshot
Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis
inferred← citeshttps://doi.org/10.1007/s13277-015-3671-0openalex-snapshot
The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
inferred← citeshttps://doi.org/10.1007/s13665-016-0137-9openalex-snapshot
New oncogenes drivers in lung cancer—new therapeutic targets
inferred← citeshttps://doi.org/10.1007/s13665-016-0138-8openalex-snapshot
ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics
inferred← citeshttps://doi.org/10.1007/s40291-021-00564-0openalex-snapshot
Targeting Mutated KRAS Genes to Treat Solid Tumours
inferred← citeshttps://doi.org/10.1007/s41030-016-0013-3openalex-snapshot
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
inferred← citeshttps://doi.org/10.1016/b978-0-12-396967-5.00012-8openalex-snapshot
Genomics and Molecular Profiling of Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-800886-7.00023-6openalex-snapshot
Molecular Testing in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00018-4openalex-snapshot
Molecular Testing in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-52357-8.00020-2openalex-snapshot
Clinical Presentation and Prognostic Factors in Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-95697-0.00005-4openalex-snapshot
Underpinning the role of phospholipase D as a therapeutic target in cancer
inferred← citeshttps://doi.org/10.1016/b978-1-4160-4710-0.00047-xopenalex-snapshot
Clinical Aspects of Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-1-4160-5225-8.00045-3openalex-snapshot
The Use of Genetic Science in Thoracic Disease
inferred← citeshttps://doi.org/10.1016/b978-1-4377-0974-2.00076-2openalex-snapshot
Molecular Genetic Pathology of Solid Tumors
inferred← citeshttps://doi.org/10.1016/b978-1-4377-1398-5.10008-6openalex-snapshot
Adjuvant Therapy for Elderly Patients with Breast, Colon, and Lung Cancer
inferred← citeshttps://doi.org/10.1016/b978-1-4557-3383-5.00053-1openalex-snapshot
Clinical Aspects of Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.06.001openalex-snapshot
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
inferred← citeshttps://doi.org/10.1016/j.annonc.2023.04.514openalex-snapshot
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.annpat.2015.11.002openalex-snapshot
Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie
inferred← citeshttps://doi.org/10.1016/j.arbr.2012.09.011openalex-snapshot
Clinical Management of Solitary Pulmonary Micronodule: A Pilot Study
inferred← citeshttps://doi.org/10.1016/j.arbres.2012.09.012openalex-snapshot
Tratamiento clínico del micronódulo pulmonar solitario: un estudio piloto
inferred← citeshttps://doi.org/10.1016/j.bbcan.2005.08.001openalex-snapshot
K-ras as a target for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.bbrc.2006.11.091openalex-snapshot
Characterization of a novel oncogenic K-ras mutation in colon cancer
inferred← citeshttps://doi.org/10.1016/j.bone.2018.01.004openalex-snapshot
Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers
inferred← citeshttps://doi.org/10.1016/j.bulcan.2019.04.010openalex-snapshot
Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?
inferred← citeshttps://doi.org/10.1016/j.cancergen.2016.03.001openalex-snapshot
The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2013.10.010openalex-snapshot
One mouse, one patient paradigm: New avatars of personalized cancer therapy
inferred← citeshttps://doi.org/10.1016/j.cca.2015.01.023openalex-snapshot
Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cca.2018.08.040openalex-snapshot
RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ccm.2011.08.003openalex-snapshot
Molecular Biology of Lung Cancer: Clinical Implications
inferred← citeshttps://doi.org/10.1016/j.cllc.2011.09.004openalex-snapshot
Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
inferred← citeshttps://doi.org/10.1016/j.cllc.2011.10.003openalex-snapshot
The Role of Cyclin D1 Expression and Patient's Survival in Non–Small-Cell Lung Cancer: A Systematic Review With Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.cllc.2012.09.007openalex-snapshot
KRAS Mutations in Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2013.05.002openalex-snapshot
Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies
inferred← citeshttps://doi.org/10.1016/j.cllc.2013.05.004openalex-snapshot
Response to First-Line Chemotherapy in Patients With Non–Small-Cell Lung Cancer According to Epidermal Growth Factor Receptor and K-RAS Mutation Status
inferred← citeshttps://doi.org/10.1016/j.cllc.2013.11.004openalex-snapshot
Association Between Race and Survival of Patients With Non–Small-Cell Lung Cancer in the United States Veterans Affairs Population
inferred← citeshttps://doi.org/10.1016/j.cllc.2013.11.005openalex-snapshot
Genetic Mutation Screen in Early Non–Small-Cell Lung Cancer (NSCLC) Specimens
inferred← citeshttps://doi.org/10.1016/j.cllc.2014.06.002openalex-snapshot
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
inferred← citeshttps://doi.org/10.1016/j.cllc.2018.12.009openalex-snapshot
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.07.004openalex-snapshot
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.cllc.2020.09.011openalex-snapshot
Clinical Characteristics, Treatments, and Concurrent Mutations in Non–Small Cell Lung Cancer Patients With NF1 Mutations
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2016.08.004openalex-snapshot
Identification of informative genes and pathways using an improved penalized support vector machine with a weighting scheme
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2021.104946openalex-snapshot
Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D
inferred← citeshttps://doi.org/10.1016/j.coph.2013.03.010openalex-snapshot
Novel therapeutic targets in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2009.11.006openalex-snapshot
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2016.12.005openalex-snapshot
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
inferred← citeshttps://doi.org/10.1016/j.csbj.2022.03.035openalex-snapshot
Machine learning application in personalised lung cancer recurrence and survivability prediction
inferred← citeshttps://doi.org/10.1016/j.ctarc.2020.100200openalex-snapshot
KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctrv.2007.01.006openalex-snapshot
Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?
inferred← citeshttps://doi.org/10.1016/j.ctrv.2020.102070openalex-snapshot
KRAS: From undruggable to a druggable Cancer Target
inferred← citeshttps://doi.org/10.1016/j.currproblcancer.2024.101106openalex-snapshot
Current perspectives of KRAS in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.cytogfr.2025.06.001openalex-snapshot
Exploring AI tools and multi-omics for precision medicine in lung cancer therapy
inferred← citeshttps://doi.org/10.1016/j.drudis.2013.11.018openalex-snapshot
The end of KRAS, and other, cancers? A new way forward
inferred← citeshttps://doi.org/10.1016/j.ejca.2008.03.006openalex-snapshot
Prognostic versus predictive value of biomarkers in oncology
inferred← citeshttps://doi.org/10.1016/j.ejca.2014.04.001openalex-snapshot
Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
inferred← citeshttps://doi.org/10.1016/j.ejca.2018.05.001openalex-snapshot
KRAS: Reasons for optimism in lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejcsup.2013.07.023openalex-snapshot
Prognostic factors in resected lung carcinomas
inferred← citeshttps://doi.org/10.1016/j.ejmech.2016.09.049openalex-snapshot
K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174256openalex-snapshot
Preclinical evidence of synergism between atovaquone and chemotherapy by AMPK-dependent mitochondrial dysfunction
inferred← citeshttps://doi.org/10.1016/j.gpb.2016.11.005openalex-snapshot
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine
inferred← citeshttps://doi.org/10.1016/j.heliyon.2020.e03488openalex-snapshot
Association of promoter methylation of RASSF1A and KRAS mutations in non-small cell lung carcinoma in Kashmiri population (India)
inferred← citeshttps://doi.org/10.1016/j.hemonc.2021.02.004openalex-snapshot
The Hispanic Paradox in Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2018.09.004openalex-snapshot
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics
inferred← citeshttps://doi.org/10.1016/j.jasc.2014.08.002openalex-snapshot
Molecular diagnostic testing of cytology specimens: current applications and future considerations
inferred← citeshttps://doi.org/10.1016/j.jtcvs.2010.08.026openalex-snapshot
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center
inferred← citeshttps://doi.org/10.1016/j.jtcvs.2020.05.097openalex-snapshot
The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features
inferred← citeshttps://doi.org/10.1016/j.jtho.2015.11.010openalex-snapshot
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1016/j.jtho.2018.12.013openalex-snapshot
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.01.020openalex-snapshot
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
inferred← citeshttps://doi.org/10.1016/j.jtho.2019.03.004openalex-snapshot
KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations
inferred← citeshttps://doi.org/10.1016/j.jtho.2023.03.015openalex-snapshot
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
inferred← citeshttps://doi.org/10.1016/j.jtho.2026.103565openalex-snapshot
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2020.100052openalex-snapshot
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2020.100140openalex-snapshot
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
inferred← citeshttps://doi.org/10.1016/j.jtocrr.2021.100261openalex-snapshot
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
inferred← citeshttps://doi.org/10.1016/j.lungcan.2006.06.009openalex-snapshot
Prognostic role of K-Ras mutations in non-small cell lung cancer: Still an issue for open debate
inferred← citeshttps://doi.org/10.1016/j.lungcan.2007.05.003openalex-snapshot
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2008.11.020openalex-snapshot
Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas
inferred← citeshttps://doi.org/10.1016/j.lungcan.2009.09.010openalex-snapshot
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
inferred← citeshttps://doi.org/10.1016/j.lungcan.2011.06.005openalex-snapshot
Predictive markers in the adjuvant therapy of non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2012.10.010openalex-snapshot
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2012.11.016openalex-snapshot
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2013.03.019openalex-snapshot
Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
inferred← citeshttps://doi.org/10.1016/j.lungcan.2013.11.010openalex-snapshot
KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies
inferred← citeshttps://doi.org/10.1016/j.lungcan.2013.12.010openalex-snapshot
Molecular testing in oncology: Problems, pitfalls and progress
inferred← citeshttps://doi.org/10.1016/j.lungcan.2013.12.013openalex-snapshot
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
inferred← citeshttps://doi.org/10.1016/j.lungcan.2014.10.004openalex-snapshot
COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours
inferred← citeshttps://doi.org/10.1016/j.lungcan.2015.10.012openalex-snapshot
Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?
inferred← citeshttps://doi.org/10.1016/j.lungcan.2018.03.003openalex-snapshot
Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients
inferred← citeshttps://doi.org/10.1016/j.lungcan.2018.06.023openalex-snapshot
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2018.07.013openalex-snapshot
KRAS-Mutant non-small cell lung cancer: From biology to therapy
inferred← citeshttps://doi.org/10.1016/j.lungcan.2019.03.027openalex-snapshot
Response to comment on: ‘Synchronous multiple non-small cell lung cancers in an allograft lung recipient’
inferred← citeshttps://doi.org/10.1016/j.lungcan.2020.06.030openalex-snapshot
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.02.005openalex-snapshot
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
inferred← citeshttps://doi.org/10.1016/j.lungcan.2021.04.002openalex-snapshot
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.03.015openalex-snapshot
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.lungcan.2024.107510openalex-snapshot
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
inferred← citeshttps://doi.org/10.1016/j.lungcan.2025.108573openalex-snapshot
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival
inferred← citeshttps://doi.org/10.1016/j.metabol.2010.12.002openalex-snapshot
Insulin resistance: an independent risk factor for lung cancer?
inferred← citeshttps://doi.org/10.1016/j.prp.2017.12.018openalex-snapshot
Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations
inferred← citeshttps://doi.org/10.1016/j.rmr.2010.05.003openalex-snapshot
Un regard simple sur la biologie moléculaire du cancer bronchique : K-Ras
inferred← citeshttps://doi.org/10.1016/j.rmr.2015.05.012openalex-snapshot
KRAS et adénocarcinome bronchique. Entre déceptions et espoirs
inferred← citeshttps://doi.org/10.1016/j.rmr.2016.01.007openalex-snapshot
Épidémiologie moléculaire du cancer bronchique
inferred← citeshttps://doi.org/10.1016/j.semcancer.2018.01.016openalex-snapshot
Targeting the RAS-dependent chemoresistance: The Warburg connection
inferred← citeshttps://doi.org/10.1016/j.talanta.2018.04.083openalex-snapshot
The classification of lung cancers and their degree of malignancy by FTIR, PCA-LDA analysis, and a physics-based computational model
inferred← citeshttps://doi.org/10.1016/j.thorsurg.2006.07.001openalex-snapshot
Novel Therapies Targeting Signaling Pathways in Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.xcrm.2020.100186openalex-snapshot
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
inferred← citeshttps://doi.org/10.1016/j.xhgg.2024.100320openalex-snapshot
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/s0272-5231(03)00062-5openalex-snapshot
Molecular biology of lung cancer: Clinical implications
inferred← citeshttps://doi.org/10.1016/s0305-7372(10)70016-5openalex-snapshot
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
inferred← citeshttps://doi.org/10.1016/s1470-2045(11)70189-9openalex-snapshot
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
inferred← citeshttps://doi.org/10.1016/s1470-2045(12)70489-8openalex-snapshot
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
inferred← citeshttps://doi.org/10.1016/s1556-0864(15)31506-9openalex-snapshot
The Ras/Raf/MAPK Pathway
inferred← citeshttps://doi.org/10.1016/s1877-1203(12)70314-2openalex-snapshot
Le cancer broncho-pulmonaire sans mutation EGFR ni remaniement ALK-EML4 : vers de nouvelles cibles et de nouvelles thérapies ?
inferred← citeshttps://doi.org/10.1016/s1877-1203(13)70450-6openalex-snapshot
Mutation de l’EGFR, de l’étude du gène à la pratique clinique : exemplarité ou exception ?
inferred← citeshttps://doi.org/10.1016/s1877-1203(14)70584-1openalex-snapshot
Aspects biologiques des cancers bronchiques
inferred← citeshttps://doi.org/10.1016/s1877-1203(16)30013-1openalex-snapshot
Facteurs pronostiques et cancers bronchopulmonaires
showing the first 200 of 580
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.